NCT01961453

Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function

Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Corporal Michael J. Crescenz VA Medical Center · Federal
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to test whether treatment with isosorbide mononitrate will improve left ventricular hypertrophy ("thickening") which puts people at risk for developing heart failure. Once it develops, heart failure is a very serious condition and thus it is important to find ways to prevent it from happening. The investigators have reasons to believe that dilating the blood vessels with this specific medication will improve the thickening of the heart, which increases the risk of heart failure.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Isosorbide Mononitrate, sustained release	60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
DRUG	Placebo capsule	One capsule of placebo administered once daily at 8 am.

Timeline

• Start date: 2013-08-01
• Primary completion: 2016-01-01
• Completion: 2016-01-01
• First posted: 2013-10-11
• Last updated: 2016-08-11

Locations

1 site across 1 country: United States